Research programme: TRIM7 inhibitors - Shattuck Labs
Latest Information Update: 29 Apr 2024
At a glance
- Originator Shattuck Labs
- Class Antineoplastics; Small molecules
- Mechanism of Action TRIM7 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer